Overview

* Standard BioTools ( LAB ) Q2 revenue falls 3% yr/yr to $21.8 mln

* Adjusted EBITDA beats estimates

* Co announces SomaLogic sale to Illumina for up to $425 mln

Outlook

* Standard BioTools ( LAB ) expects 2025 revenue between $165 mln and $175 mln

* Company anticipates 2025 revenue from continuing operations of $78 mln to $83 mln

* Standard BioTools ( LAB ) targets adjusted EBITDA break-even in 2026

* Company sees high single-digit decline in Americas academic revenue due to NIH pressures

Result Drivers

* REVENUE DECLINE - Revenue from continuing operations decreased by 3% year-over-year to $21.8 mln, with the decline attributed to capital constraints in global end-markets impacting instrument sales

* CONSUMABLES GROWTH - Consumables revenue increased by 18% year-over-year, driven by growth across imaging, flow, and microfluidics product lines

* GROSS MARGIN IMPROVEMENT - Gross margins improved to 48.8% in Q2 2025 from 46.1% in Q2 2024, attributed to product mix and improvements from Standard BioTools Business System (SBS)

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $21.80

Revenue mln

Q2 EPS -$0.09

Q2 Net -$33.46

Income mln

Q2 Beat -$16.10 -$18 mln

Adjusted mln (3

EBITDA Analysts

)

Q2 Gross 48.8%

Margin

Q2 54.1%

Adjusted

Gross

Margin

Q2 -$25.70

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Standard BioTools Inc ( LAB ) is $1.93, about 32.2% above its August 8 closing price of $1.31

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)